Clincosm LogoSign in Get a demo

Refractory Lymphoma

Showing 1 - 25 of 34
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Brain Stem Tumor, Pineal Region Tumor, Recurrent Lymphoma Trial in United States (Entinostat, Laboratory Biomarker Analysis,

    Completed
    Has Results
    • Brain Stem Neoplasm
    • +9 more
    • Birmingham, Alabama
    • +20 more
    Jan 6, 2023

    Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma Trial in United States (Elimusertib)

    Recruiting
    • Recurrent Alveolar Rhabdomyosarcoma
    • +7 more
    • Birmingham, Alabama
    • +28 more
    Jan 26, 2023

    T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)

    Recruiting
    • T-lymphoblastic Lymphoma
    • +5 more
    • BCL2 Inhibitor plus IM2 regimen
    • Shanghai, Shanghai, China
      Shanghai General hospital,Shanghai Jiao Tong University School o
    Jan 10, 2023

    Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
    • +5 more
    • (no location specified)
    Dec 2, 2022

    Recurrent Lymphoma, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Irinotecan,

    Active, not recruiting
    Has Results
    • Recurrent Lymphoma
    • +5 more
    • Birmingham, Alabama
    • +19 more
    Oct 20, 2022

    Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,

    Withdrawn
    • Constitutional Mismatch Repair Deficiency Syndrome
    • +11 more
    • Biospecimen Collection
    • +2 more
    • Palo Alto, California
    • +8 more
    Sep 9, 2022

    Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

    Recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +37 more
    • Birmingham, Alabama
    • +171 more
    Aug 24, 2022

    Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +49 more
    • Birmingham, Alabama
    • +1429 more
    Aug 17, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Trametinib Dimethyl Sulfoxide
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Aug 13, 2022

    Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

    Recruiting
    • Mantle Cell Lymphoma
    • Refractory Lymphoma
    • Boston, Massachusetts
    • +1 more
    Aug 8, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Biopsy
    • +3 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Aug 5, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)

    Active, not recruiting
    Has Results
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Tumor in the CNS, Recurrent Diffuse Intrinsic Pontine Glioma Trial

    Active, not recruiting
    • Diffuse Midline Glioma, H3 K27M-Mutant
    • +10 more
    • FACT Complex-targeting Curaxin CBL0137
    • Birmingham, Alabama
    • +19 more
    Jun 29, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

    Recruiting
    • Advanced Lymphoma
    • +13 more
    • BET Bromodomain Inhibitor ZEN-3694
    • +2 more
    • New Haven, Connecticut
      Yale University Cancer Center LAO
    Jun 29, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Afatinib

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Afatinib Dimaleate
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Defactinib Hydrochloride
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent

    Recruiting
    • Clonal Cytopenia of Undetermined Significance
    • +6 more
    • Ascorbic Acid
    • +12 more
    • Scottsdale, Arizona
    • +4 more
    May 26, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Feb 4, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Feb 4, 2022

    Solving Riddles Through Sequencing

    Recruiting
    • Leukemia
    • +5 more
    • Next Generation Sequencing
    • Munich, Germany
      MLL Munich Leukemia Laboratory
    Jan 19, 2022

    Polatuzumab Vedotin in Relapsed and Refractory Diffuse Large B

    Completed
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Lymphoma
      • Taipei, Taiwan
        National Taiwan University Hospital
      Aug 8, 2021

      Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor

      Completed
      Has Results
      • Advanced Lymphoma
      • +5 more
      • FGFR Inhibitor AZD4547
      • Philadelphia, Pennsylvania
        ECOG-ACRIN Cancer Research Group
      Jun 8, 2021